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Neurite outgrowth is essential for brain development and the recovery of brain injury and
neurodegenerative diseases. In this study, we examined the role of the neurotrophic
factor MANF in regulating neurite outgrowth. We generated MANF knockout (KO)
neuro2a (N2a) cell lines using clustered regularly interspaced short palindromic repeats
(CRISPR)/Cas9 and demonstrated that MANF KO N2a cells failed to grow neurites
in response to RA stimulation. Using MANF siRNA, this finding was confirmed in
human SH-SY5Y neuronal cell line. Nevertheless, MANF overexpression by adenovirus
transduction or addition of MANF into culture media facilitated the growth of longer
neurites in RA-treated N2a cells. MANF deficiency resulted in inhibition of Akt, Erk,
mTOR, and P70S6, and impaired protein synthesis. MANF overexpression on the other
hand facilitated the growth of longer neurites by activating Akt, Erk, mTOR, and P70S6.
Pharmacological blockade of Akt, Erk or mTOR eliminated the promoting effect of MANF
on neurite outgrowth. These findings suggest that MANF positively regulated neurite
outgrowth by activating Akt/mTOR and Erk/mTOR signaling pathways.
Keywords: MANF, neurotrophic factor, neurite outgrowth, neuronal differentiation, Erk/mTOR, Akt/mTOR, protein
synthesis

INTRODUCTION
Neurite outgrowth is the first step for the formation of axons and dendrites, which are necessary
components for the development of a functional neuronal network. Proper neurite outgrowth is
not only important for the normal development of the nervous system, but may also facilitate the
recovery of traumatic brain injury and neurodegenerative disorders such as Parkinson’s disease
(PD), Alzheimer’s disease (AD), and Amyotrophic lateral sclerosis (ALS) (Gouel et al., 2019;
Houlton et al., 2019). Neurite outgrowth requires the synthesis and reorganization of cytoskeleton
proteins including actin and microtubules (Rodriguez et al., 2003; Flynn, 2013). The dynamic
of cytoskeleton elongation, branching, and retraction is regulated by various factors such as
transcription factors that governs gene expression for neuron differentiation (Paolino et al., 2018)
and cell adhesive molecules that interact with and remodel cytoskeleton and activate gene
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adenosine monophosphate (cAMP) treatments (Salto et al.,
2015). We demonstrated that MANF was required for RAinduced neurite outgrowth. MANF regulation of neurite
outgrowth was mediated by Akt/mTOR and Erk/mTOR signaling
pathways and protein synthesis.

expression (Missaire and Hindges, 2015; Leshchyns’ka and
Sytnyk, 2016). Moreover, neurite outgrowth is also regulated by
neurotrophic factors (NTF) that activate cell signaling pathways
for neuron differentiation and migration, and support neuron
survival and synaptic function (da Silva and Dotti, 2002;
Cui, 2006).
Mesencephalic astrocyte-derived neurotrophic factor
(MANF), also known as arginine-rich, mutated in early stage
tumors (Armet), together with cerebral dopamine neurotrophic
factor (CDNF) form a novel family of neurotrophic factors
in vertebrate (Petrova et al., 2003; Lindholm et al., 2007).
MANF is an endoplasmic reticulum (ER)-stress inducible
protein, and its expression and secretion can be regulated
by ER-stress (Mizobuchi et al., 2007; Oh-Hashi et al., 2012).
MANF is broadly expressed in multiple developing and mature
tissues including the central nervous system. In rodent brain,
MANF is widely expressed in all brain regions during early
developmental stages and declined gradually when the brain
matures except for certain brain regions in the cerebral cortex,
hippocampus, and cerebellar Purkinje cells, suggesting the role
of MANF in neuron differentiation (Lindholm et al., 2008; Wang
et al., 2014; Yang et al., 2014; Danilova et al., 2019). Increasing
evidence have shown that MANF promotes the development and
survival of neurons in both normal and pathological conditions
(Petrova et al., 2003; Palgi et al., 2009; Voutilainen et al., 2009;
Airavaara et al., 2010; Chen et al., 2012). MANF is required
for dopaminergic neuron survival in Drosophila and zebrafish
(Palgi et al., 2009; Chen et al., 2012), and selectively protects
dopaminergic neuron in rat medial ventral mesencephalon
cell cultures in vitro (Petrova et al., 2003). In rat PD model
induced by 6-hydroxydopamine (6-OHDA), intrastriatally
injection of MANF protects nigrostriatal dopaminergic nerves
from degeneration (Voutilainen et al., 2009). Overexpression
of MANF ameliorates the loss of Purkinje cells in a mouse
model of spinocerebellar ataxia (Yang et al., 2014) and promotes
neural progenitor cells migration and differentiation in a
rat cortical stroke model (Tseng et al., 2017a). In addition,
MANF is also reported to facilitate retinal ganglion cells and
photoreceptor cells regeneration in the retina by regulating
neuroinflammation and immune response (Neves et al., 2016;
Gao et al., 2017; Lu et al., 2018). Similarly, CDNF has also been
reported to be neuroprotective in animal models of PD, AD, and
periphery nerve injury (Lindholm et al., 2007; Cheng et al., 2013;
Kemppainen et al., 2015).
Recently, a study using conventional MANF knockout mice
(Manf −/− ) revealed that MANF may be involved in neurite
outgrowth (Tseng et al., 2017b). Manf −/− cortex showed
decreased dendrite and axon length, while MANF deficient
neural stem cells (NSCs) have impaired ability to grow neurites
in culture. However, the mechanism and cellular signaling
involved in MANF regulation neurite outgrowth remain unclear.
In the present study, we used mouse neuro2a (N2a) cells
to investigate the mechanisms underlying MANF regulation
of neurite outgrowth. N2a cells are a neuronal cell line
model widely used for studying neuronal differentiation; they
differentiate into neuron-like cells in response to stimulants
such as serum starvation, retinoic acid (RA), and cyclic
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MATERIALS AND METHODS
Materials
The following cells and materials were used: N2a (CCL-131),
SH-SY5Y (CRL-2266) and HEK293 (CRL-1573) cells were from
ATCC (Manassas, VA, United States); MEM (11095-080), high
glucose DMEM (10569-010), L-methionine free DMEM (21013024), FBS, antibiotic-antimycotic (15240112), GeneArt Genomic
Cleavage Detection Kit (A24372), and Lipofectamine 3000
Reagent (L3000008) were from Life Technologies (Carlsbad,
CA, United States); all-trans RA (R2625), crystal violet acetate
(C5042), MTT (M5655), anhydrous DMSO (276855), DAPI
(D9542), Akt activator SC79 (SML0749), and mTOR activator
MHY1485 (SML0810) were from Sigma-Aldrich (St. Louis, MO,
United States); PFA (15714) was from Electron Microscopy
Sciences (Hatfield, PA, United States); recombinant human
MANF (hMANF) (MANF-536H) was from Creative BioMart
(New York, NY, United States); control CRISPR/Cas9 plasmid
(sc-418922), mouse ARP double nickase plasmid (sc-428989NIC), UltraCruz transfection reagent (sc-395739), plasmid
transfection medium (sc-108062), and Akt inhibitor MK2206 dihydrochloride (sc-364537) were from Santa Cruz
Biotechnology (Dallas, TX, United States); Erk activator PDBu
(12808), Erk inhibitor PD98059 (9900), and mTOR inhibitor
Torin 1 (14379) were from Cell Signaling Technology (Beverly,
MA, United States); pGEM-T-easy vector (A1360) was from
Promega (Madison, WI, United States); 10-beta competent
E. coli (C3019I) was from New England Biolabs (Ipswich,
MA, United States); scrambled siRNA-GFP lentivector (LV015G), Manf siRNA-GFP lentivector (279970940495), MANF-HA
adenovirus (mouse) (279970540200), and CMV Null control
adenovirus (000047A) were from Applied Biological Materials
(Richmond, BC, Canada); PureLink Expi Endotoxin-free Maxi
Plasmid Purification Kit (A31231) was from Thermo Fisher
Scientific (Waltham, MA, United States); VECTASHIELD
mounting medium (H-1400 and H-1500) was from Vector
Laboratories (Burlingame, CA, United States); DC protein assay
kit (5000112) was from Bio-Rad Laboratories (Hercules, CA,
United States); Click-iT HPG Alexa Fluor Protein Synthesis
Assay Kits (C10428) was from Invitrogen (Grand Island,
NY, United States).
The following antibodies were used: anti-α-tubulin (T5168,
Sigma-Aldrich); anti-ARMET/ARP (MANF) (ab67271 for
C-terminus and ab67203 for N-terminus, Abcam, Cambridge,
MA, United States); anti-HA-Tag (CST 3724), anti-phospho-Akt
(Ser473) (CST9271), anti-Akt (CST9272), anti-phosphoErk1/2 (CST 9101), anti-Erk1/2 antibody (CST 9102),
anti-phospho-mTOR (Ser2448) (CST2971), anti-mTOR
(CST2972), anti-phospho-p70 S6 (CST9204), anti-p70 S6
(CST2708), anti-Cas9 (CST 14697), and anti-β-Actin (CST3700)
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they were transferred using sterile 10 µl pipette tips to 24well plates and then 6-well plates to expand. The presence of
genomic insertions or deletions (indels) in each single cell colony
were detected using the GeneArt Genomic Cleavage Detection
Kit (Life Technologies) according to the manufacture’s protocol.
Among fourteen single cell colonies we tested, five appeared
to have genomic indels. To confirm biallelic MANF knockout,
we tested at genomic DNA and protein level. Genomic DNA
was isolated from these five colonies. MANF was cloned by
PCR using primers 50 -AGTTTTTTCCAGGGGAAATGG-30 and
50 -ACCCACTACTTTCTCTCTCAG-30 , and then cloned into
the pGEM-T-easy vector (Promega) and transformed into 10beta competent E. coli (New England Biolabs) for sequencing.
Protein was also extracted from each colony and subjected to
immunoblot to test the presence of MANF protein. Ultimately,
we confirmed 2 colonies that have biallelic MANF KO. To rule
out the possibility of clonal selection, both colonies were tested
in morphometric analysis in Figure 1 and protein expression
analysis in Figures 6, 7. Since similar results were revealed
between the two clones, we used clone 1 for all other analysis.

antibodies were all from Cell Signaling Technology; secondary
antibodies conjugated to horseradish peroxidase (NA931V
and NA934V) were from GE Healthcare Life Sciences
(Pittsburgh, PA, United States); Alexa-488 conjugated antimouse (A21202), Alexa-594 conjugated anti-mouse (A11005)
and Alexa-594 conjugated anti-rabbit antibodies (A11012) were
from Life Technologies.

Cell Culture and Differentiation
Neuro2a cells and HEK293 cells were cultured in MEM
supplemented with 10% FBS and 1% antibiotic-antimycotic at
37◦ C in 5% CO2 in a humidified incubator (Symphony 5.3A,
Thermo Scientific). SH-SY5Y cells were cultured in DMEM
supplemented with 10% FBS and 1% antibiotic-antimycotic. To
induce neurite outgrowth, N2a or SH-SY5Y cells were plated
in 6-well plates at a density of 5 × 104 cells per well for 24 h.
Then growth medium was carefully removed and replaced with
differentiation media of an equal volume of MEM or DMEM
supplemented with 2% FBS at the present of 10 µM all-trans
RA for 3 days unless otherwise stated. Recombinant human
MANF (hMANF) was added into differentiation media at a final
concentration of 100 ng/ml. Differentiation media was changed
freshly every other day to ensure RA effectiveness. Neurite was
defined as the extension of neuronal processes greater than two
cell body diameters in length. To quantify neurite length, at least
five random fields were imaged for each well using Olympus
BX51 light microscope with the 40X objective. The five random
fields were selected in an X manner with four fields at the corners
and one field in the center of the well. Cells were either imaged
alive or fixed in 4% PFA for 10 min then stained with 0.5%
crystal violet for 15 min at room temperature. Neurite length was
measured from the center of the cell body to the tip of the longest
neurite using the CellSens imaging software (Olympus, Tokyo,
Japan). Morphometrics analysis was performed independently by
two or more different investigators. To quantify the percentage of
cells with neurite, the total cell numbers and cells with neurite in
each field were counted with ImageJ.

siRNA Transfection
Scrambled siRNA-GFP and Manf siRNA-GFP lentivector
plasmids were purchased from Applied Biological Materials
(Richmond, BC, Canada) with the MANF siRNA target sequence
50 -TCAAAGACAGAGATGTCACATTTTCACCA-30
cloned
into the piLenti-siRNA-GFP plasmid backbone. The siRNA is
driven by the U6 promotor followed by the GFP driven by the
CMV promotor. The plasmids were subcloned and amplified
in 10-beta competent E. coli cells (New England Biolabs), and
purified using PureLink Expi Endotoxin-free Maxi Plasmid
Purification Kit (Thermo Fisher Scientific). Either 2.5 µg of
scrambled siRNA or Manf siRNA lentivector plasmids were
transfected into N2a or SH-SY5Y cells using Lipofectamine 3000
Reagent (Life Technologies) according to the manufacturer’s
instruction. Cells were subject to subsequent analysis.

Adenovirus Transduction

CRISPR Transfection and MANF
Knockout Single Cell Colony Isolation

Crude viral stock of MANF-HA adenovirus (mouse), referred
to AD-MANF thereafter, and CMV Null control adenovirus,
referred to AD-vector thereafter (Applied Biological Materials)
were prepared at titer ranging from 1 × 107 to 1 × 108 pfu/ml
by manufacture and then amplified in HEK293 cells according
to the manufacture’s instruction. Briefly, 3 × 106 HEK293 cells
were plated in 10 cm dishes and incubated with 100 µl crude
viral stock until 90% of the cells were rounded up and detached.
Adenovirus-containing HEK293 cells were collected with culture
media and placed at −80◦ C for 30 min and then in 37◦ C water
bath for 15 min to thaw. Repeat the freeze and thaw for 3 times.
Cell debris were pelleted at 3000 rpm for 15 min and supernatant
with viral particles were used to transduce N2a cells. N2a cells
were transduced with either CMV Null control or MANF-HA
adenovirus by incubating 120 µl per well in 6-well plate for 3 h.
Three hours later, culture media with adenovirus were removed
and replaced with fresh growth media. Cells were subject to
subsequent analysis.

Control CRISPR/Cas9 plasmid was referred to control CRISPR
thereafter and mouse ARP double nickase plasmid was referred to
MANF CRISPR thereafter. Control CRISPR has a GFP marker for
visually confirmation of successful transfection. MANF CRISPR
consists a pair of plasmids both targeting the exon 2 of mouse
Manf gene. One plasmid contains a puromycin resistance gene,
the other one has a GFP marker. N2a cells were seeded onto
6-well plate to grow to 70% confluence and were transfected
with 1 µg of either control or MANF CRISPR using UltraCruz
transfection reagent and plasmid transfection medium according
to the manufacture’s protocol. GFP-positive cells were selected
by flow cytometry 48 h after the transfection. MANF CRISPR
transfected cells that were GFP-positive were further selected by
1 µg/ml puromycin for 5 days, then diluted and plated onto
10 cm culture dishes at 1 × 103 cells/dish to form single cell
colonies. Once single cell colonies were formed and large enough,
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FIGURE 1 | Loss of MANF inhibits RA-induced neurite outgrowth. Stable N2a cell lines of MANF knockout (KO) were established as described in the Materials and
Methods. (A) Protein was collected from control and MANF KO cell lysates and analyzed by immunoblotting with MANF antibody. β-actin was used as a loading
control. The size of the proteins (kDa) was labeled next to each band. (B) Immunofluorescent staining showed MANF expression in control cells and no signal in
MANF KO cells. Cell nuclei were stained by DAPI. (C) Representative images of control and MANF KO cells treated with DMSO or RA for 3 days. Cells were fixed
and stained with crystal violet for visualization. Average neurite length (D) and percentage of cells that bear neurites (E) were measured, and analyzed by One-way
ANOVA. In cases where significant differences were detected, specific post hoc comparisons between treatment groups were examined with the Tukey’s test.
***P < 0.0001, n.s. not statistically significant. The data were expressed as the mean ± SEM of three independent experiments.

and 0.5% Nonidet P-40 (NP-40), 0.25% sodium dodecyl sulfate
(SDS), with freshly added protease inhibitors of 5 µg/ml
leupeptin, 5 µg/ml aprotinin, 3 mM sodium orthovanadate, and
0.3 mg/ml phenylmethanesulfonyl fluoride (PMSF). Lysed cells
were centrifuged at 10,000 × g for 30 min at 4◦ C, and the
supernatant fraction was collected. Protein concentration was
determined using the DC protein assay (Bio-Rad Laboratories)
according the manufacture’s instruction.
Immunoblotting was performed as previously described (Li
et al., 2019; Pillai-Kastoori et al., 2020a,b). In brief, 20–
30 µg protein samples were separated by SDS-PAGE on 12%
polyacrylamide gels by electrophoresis. Separated proteins were
then transferred to nitrocellulose membranes and blocked in
5% BSA/ 1xTBS/0.05% Tween-20 for 1 h at room temperature
prior to incubation with primary antibodies at 4◦ C overnight.
The primary antibodies used and the final dilutions were
as follows: anti-ARMET/ARP (MANF), anti-HA-Tag, antiphospho-Akt (Ser473), anti-Akt, anti-phospho-Erk1/2, antiErk1/2 antibody, anti-phospho-mTOR (Ser2448), anti-mTOR,
anti-phospho-p70S6, anti-p70S6, anti-Cas9, and anti-β-actin
(1:1000). Subsequently, membranes were washed with TBST and
incubated with secondary antibodies conjugated to horseradish

Immunocytochemistry
Neuro2a or SH-SY5Y cells were seeded onto 24-well plates
with sterile coverslip on the bottom coated with 10 µg/ml
fibronectin. After differentiation, cells were fixed with 4% PFA
and permeabilized in 0.25% Triton X-100 in PBS for 10 min at
room temperature. Then cells were blocked with 1% BSA/2%
goat serum/PBS for 30 min and incubated with anti-α-tubulin
antibody (1:1000) 1 h at room temperature. After washing with
PBS, cells were incubated with Alexa fluor-conjugated secondary
antibodies at a dilution of 1:200. Cells on the coverslip were
counterstained with DAPI and sealed with VECTASHIELD
mounting medium (Vector Laboratories). Fluorescence images
were obtained using the Olympus IX81 inverted fluorescent
microscope (Olympus).

Protein Extraction and Immunoblotting
Protein was extracted from N2a or SH-SY5Y cells as previously
described (Xu W. et al., 2018). Briefly, cells were washed with ice
cold PBS and lysed on ice for 15 min in RIPA buffer containing
150 mM NaCl, 1 mM ethylene glycol-bis(beta-aminoethyl ether)N,N,N0 ,N0 -tetraacetic acid (EGTA), 50 mM Tris–HCl (pH 7.5),
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peroxidase (1:5000). Blots were developed using the Amersham
ECL Prime Western Blotting Detection Reagent (GE Healthcare
Life Sciences). The density of immunoblotting was quantified
using Image Lab software (Bio-Rad Laboratories).

detected, specific comparisons between treatment groups were
examined with the Tukey’s post hoc test for one-way ANOVA or
Bonferroni’s post hoc test for two-way ANOVA.

RESULTS

MTT Assay
To examine cell metabolic activity, 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) assay was used. Cells
were seeded on 96-well plates at 2 × 103 cells per well. At times
indicated, MTT was added to each well at the final concentration
of 500 µg/ml and incubated at 37◦ C for 2 h. After the incubation,
media were carefully removed and 100 µl DMSO was added to
each well to dissolve the MTT formazan. Plates were read using
the Beckman Coulter DTX 880 Multimode Detector plate reader
(Analytical Instruments, Golden Valley, MN, United States) at the
wavelength of 595 nm.

MANF Deficiency Inhibits RA-Induced
Neurite Outgrowth
Mesencephalic
astrocyte-derived
neurotrophic
factor
knockout (KO) N2a cells were generated by transfection
of MANF CRISPR/Cas9. Two single cell colonies with
biallelic MANF knockout were isolated. Immunoblotting
and immunocytochemistry revealed that MANF protein was not
present in both clones of MANF KO N2a cells (Figures 1A,B).
To examine if MANF is required for neurite outgrowth in N2a
cells, control and KO cells were treated with 10 µM RA or
DMSO control in media with 2% FBS for 3 days. The length
of neurite and percentage of cells with neurite was analyzed.
Strikingly, among 500–800 cells analyzed in three independent
experiments, significantly fewer numbers of MANF KO cells
have grown neurite and the length of neurite was significantly
shorter compared to control cells. The treatment of RA results in
about 60% control cells to grow neurites, but only ∼6% KO cells
bear neurites (Figures 1C,E). The average neurite length after
3 days of RA treatment in KO cells was only 33.27 ± 9.95 µm
for clone 1 and 36.42 ± 12.41 µm for clone 2, compared to
88.28 ± 20.59 µm for control cells (Figures 1C,D).
To determine whether the reduction of neurite outgrowth
in MANF KO cells was a consequence of general toxicity due
to MANF knockout or RA treatment, we measured the cellular
metabolic activity of clone 1 by MTT assay. We observed a
steady increase of viable and metabolically active cells for both
DMSO treated control and KO cells, indicating that MANF
knockout does not affect N2a cell metabolic activity (Figure 2A).
Interestingly, KO cells showed higher cell metabolic activity at
48 and 72 h compared to control cells. In addition, we noticed
that RA treatment slowed down cell growth and RA-treated
control cells have significantly slower proliferation rate compared
to other groups, which was in line with the fact that the majority
of RA treated control cells ceased proliferation and underwent
differentiation (Figure 2A).
To test the possibility that MANF KO cells may have delayed
neurite outgrowth in response to RA treatment, we prolonged
cells in differentiation media for 6 days and measured neurite
length each day. For control cells, we observed a gradual increase
in neurite length and by 6 days the neurite length reached to
154.45 ± 43.47 µm. However, for KO cells (clone 1 was used
for this analysis), we only observed a subtle neurite growth
to 36.94 ± 14.11 µm and it started to decline after 5 days
(Figures 2B,C).
To confirm that the inhibition of neurite outgrowth was
specific to MANF deficiency, we performed an alternative
approach of using siRNA to knockdown MANF in N2a and
SH-SY5Y cells and compared neurite length between MANF
siRNA and scramble siRNA transfected cells. MANF siRNA
sufficiently reduced about 50% MANF expression in N2a cells

Pharmacological Inhibition or Activation
of Akt, Erk, and mTOR
Cells were preincubated with Akt activator SC79 (2.5 µM), Erk
activator PDBu (2 µM), mTOR activator MHY1485 (5 µM) and
Akt inhibitor MK-2206 dihydrochloride (2.5 µM), Erk inhibitor
PD98059 (50 µM), mTOR inhibitor Torin 1 (50 nM) for 30 min
and then treated with RA as described above.

Click-iT Homopropargylglycine (HPG)
Protein Synthesis Assay
To detect the rate of protein synthesis, we utilized the ClickiT HPG Alexa Fluor Protein Synthesis Assay Kits (Invitrogen).
Control and MANF KO N2a cells were seeded onto either
fibronectin coated 96-well plates or fibronectin coated 24-well
plates with sterile coverslip on the bottom. Protein synthesis
was detected for cells treated with RA or DMSO control at 24,
48, and 72 h. An hour before the click-it reaction, media was
replaced with DMEM without L-methionine (Life Technologies)
to deplete methionine. Then cells were incubated with 50 µM
HPG in L-methionine free DMEM media for 1 h and fixed
with 4% PFA in PBS. After permeabilization in 0.5% TritonX100 in PBS, cells were incubated in Click-iT reaction cocktail at
room temperature for 30 min in dark and then cell nuclei were
counter stained with DAPI. The rate of HPG incorporation in
96-well plates was examined using the Beckman Coulter DTX
880 Multimode Detector plate reader (Analytical Instruments) at
the wavelength of 535 nm for the fluorescent intensity. Coverslips
were removed from 24-well plates and mounted onto slides and
images were taken using the Olympus IX81 inverted fluorescent
microscope (Olympus). Images were analyzed using ImageJ for
calculating the percentage of cells without HPG incorporation.

Statistical Analysis
All analyses were performed using the GraphPad Prism version
7 software. Data were expressed as mean ± SEM of three
independent experiments in each group. Differences among
experimental groups were analyzed by Student t-test, one-way
ANOVA or two-way ANOVA with p < 0.05 being considered
statistically significant. In cases where significant differences were
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FIGURE 2 | The reduction of neurite outgrowth in MANF KO cells is neither due to toxicity nor delayed process. (A) Cell metabolic activity at 0, 24, 48, and 72 h of
RA treatment was tested by MTT assay. Different letters above columns indicate significant differences between treatments as tested by two-way ANOVA followed
with the Bonferroni’s post hoc test (P < 0.05). The data were expressed as the mean ± SEM of three independent experiments. (B) Average neurite length of control
and MANF KO cells after 6 days of RA treatment was determined and analyzed by Two-way ANOVA followed with the Bonferroni’s post hoc test, ***P < 0.001. The
data were expressed as the mean ± SEM of three independent experiments. (C) Representative images of control and MANF KO cells treated with RA.

(Figures 3A,B) and 30% in SH-SY5Y cells (Figures 3E,F). Since
both scrambled siRNA and MANF siRNA plasmids contain GFP,
we were able to use the expression of GFP as an indicator for
successful transfection and analyze neurite length in GFP positive
cells. Consistent with MANF CRISPR KO cells, siRNA MANF
knockdown resulted in reduced neurite outgrowth in response to
RA treatment compared to control cells as shown by α–tubulin
labeling (Figures 3C,D,G,H). Scramble siRNA transfected N2a
cells send out neurite at an average of 137.69 ± 25.06 µm
in respond to RA treatment, while MANF siRNA transfected
N2a cells only grow neurite at 46.25 ± 20.87 µm. Similarly,
scramble siRNA transfected SH-SY5Y cells send out neurite at
an average of 92.19 ± 27.55 µm in respond to RA treatment,
while MANF siRNA transfected SH-SY5Y cells only grow neurite
at 31.68 ± 7.71 µm. All these data above suggested that MANF
deficiency inhibited neurite outgrowth.

two experiments to test whether MANF can facilitate neurite
outgrowth in response to RA treatment through its intracellular
or extracellular form, respectively. First, we examined whether
addition of extracellular MANF in the culture media can induce
neurite outgrowth in N2a cells. We found that the addition
of MANF (100 ng/ml) into the culture media alone did not
induce N2a cells to grow neurites (Figures 4A,B). However, when
MANF was combined with RA, cells grow long neurites that
reached 203.26 ± 71.02 µm after 3 days, which was significantly
longer than cells treated with RA alone (88.28 ± 20.59 µm)
(Figures 4A,B). This result suggested that extracellular MANF
can facilitate neurite outgrowth in response to RA.
Then, we induced the overexpression of MANF intracellularly
by adenovirus (AD) transduction. Adenovirus transduction did
not affect endogenous MANF expression when compared to
untransduced cells (Figures 4C,D). Immunoblotting detected
that AD-MANF transduced cells show robust exogenous MANF
expression which migrate slower than the endogenous MANF
due to the presence of HA-tag (Figures 4C,D). The expression
of exogenous MANF protein in AD-MANF transduced N2a
cells peaked around 48 h after transduction and started to
decline afterward (Supplementary Figure S1). Twelve hours
after the transduction, cells were incubated in differentiation
media for 3 days and neurite length was measured each
day. We found that AD-MANF transduced N2a cells grow
significantly longer neurites (173.83 ± 52.32 µm) compared

MANF Overexpression Facilitates
RA-Induced Neurite Outgrowth
Mesencephalic astrocyte-derived neurotrophic factor is mostly
located in the lumen of endoplasmic reticulum (ER), but it
can also be secreted under pathological conditions such as ERstress (Apostolou et al., 2008; Glembotski et al., 2012). Since
it is still unclear whether the biological function of MANF is
through its intracellular form or secreted form, we performed
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FIGURE 3 | MANF knockdown by siRNA inhibits RA-induced neurite outgrowth. N2a and SH-SY5Y cells were transfected with MANF siRNA-GFP or scramble
siRNA-GFP construct as described in the section “Materials and Methods.” (A,E) 24 h after the transfection, cells were lysed and analyzed by immunoblotting with
MANF and GFP antibodies. β-actin was used as a loading control. The size of the proteins (kDa) was labeled next to each band. (B,F) MANF protein levels were
quantified and normalized to β-actin. The data were analyzed by Student’s t test, ***P < 0.0001. The data were expressed as the mean ± SEM of three independent
experiments. (C,G) Average neurite length in scramble siRNA and MANF siRNA transfected GFP+ cells after 3 days of RA treatment was determined and analyzed
by Student’s t test, ***P < 0.0001. The data were expressed as the mean ± SEM of three independent experiments. (D,H) Representative fluorescent images
revealed GFP expression in cells with successful siRNA transfection (Green). Neurites were visualized by immunofluorescent labeling of α-tubulin (Red). Cell nuclei
were stained by DAPI. **P < 0.01.

to AD-vector transduced control cells (111.20 ± 33.83 µm)
starting at 2 days. By day 3, AD-MANF transduced cells
still have significantly longer neurites (241.66 ± 58.16 µm)
than control cells (137.82 ± 37.29 µm) (Figures 4E,F). As a
result, we concluded that both extracellular and intracellular
MANF can facilitate N2a cell neurite outgrowth in response
to RA stimulation.

the cells. Since the MANF CRISPR target sites were located
within exon 2 of mouse Manf gene, the presence of MANF
CRISPR/Cas9 in the cells was able to interfere with the expression
Manf gene carried by AD-MANF, further inhibit the expression
of exogenous MANF.
As a result, we were only able to test whether addition of
extracellular MANF can rescue the neurite outgrowth defect in
MANF KO cells. MANF KO cells were treated with DMSO or RA
with or without addition of recombinant hMANF (100 ng/ml) in
the culture media for 3 days (Figure 5). As before, neither RA
nor hMANF can induce MANF KO cells to grow neurites. In
addition, the combination of RA+hMANF also failed to induce
neurite outgrowth in MANF KO cells, suggesting that addition
of extracellular MANF is not sufficient to rescue the neurite
outgrowth defects in MANF KO cells in response to RA.

Addition of MANF in Culture Media Fails
to Rescue Neurite Outgrowth Defects in
MANF KO Cells in Response to RA
Treatment
Since both intracellular and extracellular MANF facilitates RAinduced neurite outgrowth in control N2a cells, we want to test
whether addition of MANF can rescue the neurite outgrowth
defects in MANF KO cells. We first tried to overexpress MANF
intracellularly in MANF KO cells. Unfortunately, we were
unable to reintroduce MANF back into MANF KO cells by
AD-MANF transduction for two possible reasons. First, the
transduction efficiency was much lower in KO cells compared
to control cells. As shown in Supplementary Figure S2, we
were able to detect HA signal in 85% of control cells with
correspondence strong exogenous MANF expression. However,
only 31% of KO cells showed weak HA expression and no
exogenous MANF was detected. The other reason why we were
unable to reintroduce MANF expression in KO cells was that
we still detected high level of Cas9 protein expression in KO
cells (Supplementary Figure S2D), indicating the integration
of the MANF CRISPR/Cas9 construct into the genome of

Frontiers in Molecular Neuroscience | www.frontiersin.org

MANF Regulates RA-Induced Neurite
Outgrowth Through the Activation of
Akt/mTOR and Erk/mTOR Signaling
Cascades
Since Akt/mTOR and Erk/mTOR are key regulators for neurite
outgrowth, we then tested whether these signaling cascades were
involved in the role of MANF in regulating neurite outgrowth.
We first examined changes in the expression of Akt/mTOR and
Erk/mTOR cascades genes in control and MANF KO cells, and
AD-vector and AD-MANF transduced cells within 12 h of RA
treatment. As expected, in control and AD-vector transduced
cells, the initiation of RA-induced neurite outgrowth was
correlated with an upregulation of Akt/mTOR and Erk/mTOR
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FIGURE 4 | MANF overexpression facilitates RA-induced neurite outgrowth. (A) Representative images of N2a cells treated with DMSO or RA for 3 days with or
without addition of recombinant hMANF (100 ng/ml). Cells were fixed and stained with crystal violet for visualization. (B) Average neurite length was measured, and
analyzed by One-way ANOVA followed with the Tukey’s post hoc test, ***P < 0.0001 and n.s. not statistically significant compared to DMSO treated cells,
### P < 0.0001 compared to RA treated cells. The data were expressed as the mean ± SEM of three independent experiments. (C) Cells were lysed 48 h after
adenovirus transduction and subjected to immunoblot to determine levels of MANF and HA tag expression. The size of the proteins (kDa) was labeled next to each
band. (D) Endogenous and exogenous MANF protein levels were quantified and normalized to β-actin. The data were analyzed by Student’s t test, ***P < 0.0001.
The data were expressed as the mean ± SEM of three independent experiments. (E) Representative images of AD-vector and AD-MANF transduced cells treated
with RA for 24, 48, and 72 h. (F) Average neurite length of AD-vector and AD-MANF transduced cells after RA treatment was determined, and analyzed by Two-way
ANOVA followed with the Bonferroni’s post hoc test, ***P < 0.001. The data were expressed as the mean ± SEM of three independent experiments.

to control cells. RA failed to induce the phosphorylation of
Akt in MANF KO cells (Figures 6A,C) and the induction of
p-Erk was significantly reduced from 11-fold in control cells
to only 6-fold in KO cells (Figures 6A,D). As a result, the
level of p-mTOR and p-P70S6 was also reduced in MANF KO
cells (Figures 6A,E,F). On the contrary, AD-MANF transduced
cells overexpressing intracellular MANF (Figure 7A) showed
significantly elevated expression of p-Akt and p-Erk compared
to AD-vector transduced cells (Figures 7A,C,D). p-mTOR
and p-P70S6 were also significantly upregulated in MANF
overexpressed N2a cells (Figures 7B,E,F).

signaling pathways. We observed a steady 2-fold increase of
p-Akt in control cells by the end of the 12 h RA-treatment
(Figures 6A,C). The expression of p-Erk in control cells peaked
at 1–3 h to 11-fold and then started to decline (Figures 6A,D).
Following the activation of Akt and Erk, the phosphorylation
of mTOR and P70S6 in control cells was also increased to 1.4fold at 3 h and 2-fold at 6 h, respectively, and then started to
decline (Figures 6A,E,F). Similar Akt/mTOR and Erk/mTOR
activation was observed in RA-treated AD-vector transduced
cells (Figure 7). Strikingly, RA-treated MANF KO cells exhibit
significantly less extent of Akt and Erk activation compared

Frontiers in Molecular Neuroscience | www.frontiersin.org

8

September 2020 | Volume 13 | Article 560020

Wen et al.

MANF Regulates Neurite Outgrowth

FIGURE 5 | Addition of extracellular hMANF fails to rescue the neurite outgrowth defects in MANF KO cells. (A) Representative images of MANF KO N2a cells
treated with DMSO or RA for 3 days with or without addition of recombinant hMANF (100 ng/ml). Cells were fixed and stained with crystal violet for visualization.
(B) Average neurite length was measured, and analyzed by One-way ANOVA followed with the Tukey’s post hoc test, n.s. not statistically significant. The data were
expressed as the mean ± SEM of three independent experiments.

PDBu is a potent activator of protein kinase C (PKC), which
further activates Erk as a downstream PKC target. SC79 inhibits
Akt membrane translocation and enhances Akt phosphorylation.
MHY1485 is a cell-permeable activator of mTOR that has been
shown to increase the phosphorylation of mTOR at Ser2448. We
found that when treated separately, none of the activators was
able to rescue the phenotype (Figure 9B). Considering that it
might not be sufficient for the neurite to grow by activating just
one of the signaling pathways, we then treated the cells with two
or all three activators simultaneously. Interestingly, when treated
with Erk and Akt activators together, we observed a slight but
significant increase in the neurite length in some of the MANF
KO cells from 30.38 ± 9.89 to 40.92 ± 18.16 µm (Figures 9A,B).
However, none of the other combinations of treatments can
rescue the defects of RA-induced neurite outgrowth in MANF
KO cells (Figure 9B).

To further confirm that MANF facilitates RA-induced neurite
outgrowth via activating Erk/mTOR and Akt/mTOR signaling
pathways, control cells were treated with RA and MANF
at the presence of Erk inhibitor PD98059 (50 µM), Akt
inhibitor MK2206 (2.5 µM), and mTOR inhibitor Torin 1
(50 nM), respectively. PD98059 is a highly selective MEK1
inhibitor, inhibiting the phosphorylation Erk1/2. MK2206 binds
to and inhibits the phosphorylation of Thr308 and Ser 473
of Akt, resulting in the inhibition of the PI3K/Akt signaling
pathway. Torin 1 is a strong inhibitor for both mTORcontaining complexes, mTORC1 and mTORC2. Treatment of
either inhibitors could cause reduced cell proliferation and
apoptosis. Dosages for each inhibitor were tested and the
minimum dosage that was not toxic to the cells (data not shown)
and showed effective inhibition of the phosphorylation of Erk,
Akt, and mTOR (Supplementary Figure S3), respectively, was
used. As expected, the neurite of RA-stimulated N2a cells reached
103.01 ± 27.63 µm after 3 days of treatment. The addition of
Erk, Akt, or mTOR inhibitors significantly reduced RA-induced
neurite to 34.74 ± 15.32, 36.39 ± 13.77, and 30.75 ± 9.17 µm,
respectively (Figure 8). More importantly, the inhibitors also
eliminated the effect of MANF in enhancing RA-induced neurite
outgrowth. When treated with RA plus MANF, the average
neurite length reached to 233.13 ± 71.71 µm; while the addition
of Erk, Akt, or mTOR inhibitors reduced the average neurite
length to 37.84 ± 16.46, 40.09 ± 11.16, and 31.27 ± 13.09 µm,
respectively, which were significantly shorter compared to RA
plus MANF alone (Figure 8).
Next, we tested whether treatment of Erk, Akt, and mTOR
activators can rescue the neurite outgrowth defects in MANF KO
cells in response to RA treatment. Erk activator PDBu (2 µM),
Akt activator SC79 (2.5 µM), and mTOR activator MHY1485
(5 µM) were used at the dosage which was not toxic to the
cells and showed effective activation of the phosphorylation of
Erk, Akt, and mTOR, respectively (Supplementary Figure S3).
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MANF Deficiency Impairs Protein
Synthesis
Protein synthesis is critical for neurite formation and can
be regulated by the activation of Akt/mTOR and Erk/mTOR
signaling pathways. Since our data suggests that MANF positively
regulates Akt/mTOR and Erk/mTOR signaling, we sought to
further test whether protein synthesis was affected in MANF KO
cells and whether it was involved in its defect in RA-induced
neurite outgrowth. HPG protein synthesis assay revealed that
N2a cells had robust protein synthesis. Fluorescent imaging
revealed that nascent protein was mainly localized in the cell
soma in DMSO treated control cells (Figure 10A). For RA treated
control cells, fluorescent signal was also detected in the neurites,
indicating that nascent protein was also present in the growing
neurites (Figure 10B, arrowheads). MANF KO cells also exhibit
robust fluorescent signal (Figure 10C), but it was limited to
the cell soma in both DMSO and RA treated groups, indicating
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FIGURE 6 | MANF knockout reduces RA-induced activation of Akt/mTOR and Erk/mTOR signaling pathways. (A) Control and MANF KO cells were treated with RA
for 10, 30, 60, 180, 360, and 720 min. Protein was extracted from cell lysates and subjected to immunoblot. The size of the proteins (kDa) was labeled next to each
band. (B) MANF protein levels were quantified and normalized with β-actin. (C) p-Akt protein levels were quantified and normalized with total Akt. (D) p-Erk protein
levels were quantified and normalized with total Erk. (E) p-mTOR protein levels were quantified and normalized with total mTOR. (F) p-P70S6 protein levels were
quantified and normalized with total P70S6. The data were expressed as the mean ± SEM of three independent experiments and were analyzed by Two-way
ANOVA followed with the Bonferroni’s post hoc test, *P < 0.05, **P < 0.01, ***P < 0.001.

a lack of neurite outgrowth in response to RA (Figure 10D).
Quantification of the fluorescent intensities revealed that for
both control and KO cells, RA treatment resulted in a higher
rate of protein synthesis compared to DMSO treatment, and it
increased over time (Figure 10E). However, MANF KO cells have
significantly less fluorescent signal compared to control cells. In
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addition, we noticed that regardless of RA treatment, a small
portion (<5% at 24 and 48 h, ∼10% at 72 h) of control cells
showed no nascent protein synthesis during the time of the assay
(Figures 10A,B, arrows). MANF KO cells, on the other hand,
showed significantly higher percentage of cells (∼10% at 24 h,
∼20% at 48 h, ∼35% at 72 h) that were undetectable for nascent
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FIGURE 7 | MANF overexpression enhances RA-induced activation of Akt/mTOR and Erk/mTOR signaling pathways. (A) AD-vector and AD-MANF transduced cells
were treated with RA for 10, 30, 60, 180, 360, and 720 min. Protein was extracted from cell lysates and subjected to immunoblot. The size of the proteins (kDa) was
labeled next to each band. (B) Endogenous and exogenous MANF protein levels were quantified and normalized with β-actin. (C) p-Akt protein levels were quantified
and normalized with total Akt. (D) p-Erk protein levels were quantified and normalized with total Erk. (E) p-mTOR protein levels were quantified and normalized with
total mTOR. (F) Quantification of p-P70S6 protein levels were quantified and normalized with total P70S6. The data were expressed as the mean ± SEM of three
independent experiments and were analyzed by Two-way ANOVA followed with the Bonferroni’s post hoc test, *P < 0.05, **P < 0.01, ***P < 0.001.

synthesis and the activation of Akt/mTOR and Erk/mTOR
signaling pathways.
Neuro2a and SH-SY5Y cells are common neuronal cell line
models widely used for studying neuronal differentiation in vitro
due to their ability to proliferate and to be easily transfected
compared to primary neuron. Neuronal cell lines can be induced
into neuron-like cells, where they turn on the expression of
neuronal cell markers and grow neuronal processes resembling
axons and dendrites. However, as many neuronal cell lines were
derived from immortalized neuronal tumors and have undergone
numerous proliferations that could accumulate mutations and
may not recapitulate the properties of normal neurons from
the nervous system. We used neuronal cell lines N2a and SHSY5Y to show that RA treatment induced neurite outgrowth
and MANF deficiency attenuated this process. It is noted that
a cell with longer neurites seems also to present enlarged cell

protein (Figure 10C,D, arrows). These data suggest that MANF
deficiency impairs N2a cell protein synthesis, which may further
contribute to the neurite outgrowth defects in MANF KO cells.

DISCUSSION
Neurite outgrowth is a critical process for neuron differentiation
and regeneration in neurological diseases. In this study, we
demonstrated that MANF was necessary for RA-induced
neurite outgrowth by positively regulating Akt/mTOR and
Erk/mTOR signaling pathways. Neurite outgrowth requires
protein synthesis, which is regulated by Akt/mTOR and
Erk/mTOR signaling pathways (Read and Gorman, 2009;
Doherty et al., 2000). We are the first to show that MANF
regulates neurite outgrowth through the regulation of protein
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FIGURE 8 | Pharmacological inhibition of Akt, Erk, and mTOR blocks MANF-enhanced neurite outgrowth in response to RA. (A) Representative images of N2a cells
treated with DMSO or RA or RA+inhibitors for 3 days with or without addition of recombinant hMANF (100 ng/ml). Cells were fixed and stained with crystal violet for
visualization. (B) Average neurite length was measured, and analyzed by One-way ANOVA followed with the Tukey’s post hoc test, ***P < 0.0001 compared to
DMSO treated cells, ### P < 0.0001 compared to RA treated cells. The data were expressed as the mean ± SEM of three independent experiments.

CRISPR: (1) As the effectiveness of siRNA is usually diluted out
around 3–4 days after transfection due to cell proliferation, the
generation of stable MANF knockout cells allow us to perform
experiments with a longer time span, such as the examination of
neurite outgrowth with 6 days of RA treatment, which provided
evidence of MANF knockout indeed attenuates but not just
delays RA-induced neurite outgrowth; (2) The efficiency of
siRNA transfection varies depending on the condition of cells
and transfection reagents. For example, immunoblotting analysis
confirmed that siRNA method only reduced MANF by 50%.
MANF knockout using CRISPR had a much better efficiency.
However, stable MANF knockout using CRIPSR on the other
hand, may trigger compensatory expression of other UPR genes,
and transient knock out of MANF by siRNA is able to overcome
this shortcoming.
Different from most neurotrophic factors that are secreted,
MANF is largely retained in the lumen of the ER and
is secreted under pathological conditions where ER stress
is elevated (Apostolou et al., 2008; Tadimalla et al., 2008;
Glembotski et al., 2012; Oh-Hashi et al., 2012; Henderson
et al., 2013). Under normal condition, MANF is retained
in the ER via its calcium-dependent interaction with GRP78

bodies with increased neurite caliber. This suggests that RA
treatment may also cause general growth and hypertrophy of
the cells. It is essential to confirm cell line results with primary
neurons. The role of MANF in neurite extension has been
investigated in primary neurons and neural precursors as well as
in animals. A study by Ko et al. reported that MANF was required
for the neurite extension and maintenance in cultured retinal
ganglion cells (RGCs) isolated from 3 to 5 days old rat retina (Ko
et al., 2020). Another study by Tseng et al., 2017a reported that
complete conventional MANF knockout mice exhibit impaired
neurite outgrowth in vivo, and MANF-deficient neuronal stem
cells isolated from the embryonic day 13.5 (E13.5) knockout mice
have defect in neurite extension when cultured and differentiated
in vitro (Tseng et al., 2017a). However, these studies did not
examine the underlying cellular/molecular mechanisms. Our
study used neuronal cell lines to confirm the findings and further
investigate cell signaling pathways responsible for MANF’s effect.
We used both siRNA and CRISPR to generate MANF deficient
cells and showed that loss of MANF attenuates the ability
of N2a and SH-SY5Y cells to grow neurites in response to
RA-stimulation. These methods are complementary. There are
two advantages of generating stable MANF knockout using
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FIGURE 9 | Pharmacological activation of Akt, Erk, and mTOR partially rescues neurite outgrowth defects in MANF KO cells in response to RA. (A) Representative
images of MANF KO cells treated with DMSO or RA or RA+Akt and Erk activators for 3 days. Cells were fixed and stained with crystal violet for visualization. Red
arrows indicate cells with neurite outgrow in response to RA treatment. (B) Average neurite length was measured, and analyzed by One-way ANOVA followed with
the Tukey’s post hoc test, ***P < 0.0001. The data were expressed as the mean ± SEM of three independent experiments.

FIGURE 10 | Protein synthesis is reduced in MANF KO cells. Control cells treated with DMSO (A) or RA (B) and then incubated with HPG. MANF KO cells treated
with DMSO (C) or RA (D) and then incubated with HPG. White arrows indicate cells without HPG signal (cells lacking nascent protein synthesis); white arrow heads
indicate neurites with HPG signal. (E) HPG fluorescence intensities in control and MANF KO cells were quantified and analyzed by Two-way ANOVA followed with
the Bonferroni’s post hoc test. # P < 0.05 compared to Ctrl DMSO; *P < 0.05, ***P < 0.001 compared to KO DMSO; $$$ P < 0.001 compared to KO RA. The data
were expressed as the mean ± SEM of three independent experiments. (F) Percentage of cells without HPG signal was quantified, and analyzed by Two-way
ANOVA followed with the Bonferroni’s post hoc test, ***P < 0.0001, n.s. not statistically significant. The data were expressed as the mean ± SEM of three
independent experiments.
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and stabilization, neurite branching and extension, and axon
formation (Frebel and Wiese, 2006; Read and Gorman, 2009;
Hausott and Klimaschewski, 2019). Mammalian target of
rapamycin (mTOR) is one of the major downstream effectors
of PI3K/Akt and Ras/Erk signaling pathways (Potter et al.,
2002; Ma et al., 2005). mTOR is a serine/threonine protein
kinase which is a key regulator for cell growth and metabolism
by controlling protein translation and lipogenesis (Takei and
Nawa, 2014). It promotes protein synthesis through the
phosphorylation of P70S6 kinase, which in turn phosphoactivates
the ribosomal protein S6 and lead to increased mRNA
and protein synthesis (Laplante and Sabatini, 2009). Protein
synthesis is essentially required for neurite outgrowth. Increased
requirement of new protein synthesis is accompanied with
the process of neurite initiation, branching, elongation, and
stabilization (Tojima and Ito, 2004; Flynn, 2013). Protein
synthesis is important for filopodia and neurite formation
(Gallo, 2013; Sainath and Gallo, 2015). Local protein synthesis
is critical for axon elongation and pathfinding (Twiss and
van Minnen, 2006). Decreased protein synthesis has been
reported in various neurodegenerative disorders, such as
Alzheimer’s disease (Chang et al., 2006). The activation
of PI3K/Akt/mTOR and Ras/Erk/mTOR signaling cascades
positively regulates protein synthesis, which is critical for cell
differentiation and neurite outgrowth in neurons (Fujii et al.,
1982; Takei and Nawa, 2014; Schanzenbacher et al., 2016;
Rozenbaum et al., 2018).
Several studies have suggested that MANF can activate Akt
and Erk signaling pathways. In an in vitro study, extracellular
MANF was shown to protect human neuroblastoma SH-SY5Y
cells from 6-hydroxydopamine (6-OHDA) induced cell death
via the activation of PI3K/Akt/mTOR pathway (Hao et al.,
2017). In addition to mTOR, several other downstream effectors
of the PI3K/Akt signaling pathway including GSK3β, MDM2,
and NF-κB have been reported to be activated by treatment
of recombinant hMANF in the rodent brain, which was
associated with enhanced neuron survival in neurodegenerative
diseases and intracerebral hemorrhage models (Hao et al.,
2017; Zhang et al., 2017b; Li et al., 2018; Xu M. et al.,
2018). MANF has also been reported to activate Erk in a
study showing that intracellular MANF overexpression facilitated
neuron migration and activated STAT3 and Erk in mice
SVZ explant (Tseng et al., 2017a). However, in the same
study when NSC cultures were treated with recombinant
hMANF, neither Akt nor Erk was activated, suggesting the
activation of Akt and Erk by MANF may be cell typeand context-dependent.
We showed that MANF knockout in N2a cells attenuated
RA-induced activation of Akt/mTOR and Erk/mTOR, leading to
limited neurite outgrowth. MANF overexpression on the other
hand lead to longer neurite length which was correlated with
increased activation of Akt/mTOR and Erk/mTOR in response
to RA. Treatment of Akt, Erk or mTOR inhibitors blocked
RA-induced N2a cells neurite outgrowth. Moreover, MANF
enhanced neurite outgrowth and Akt/mTOR and Erk/mTOR
activation can also be blocked by inhibition of Akt, Erk or
mTOR. We observed minimal toxic effect of these inhibitors

(glucose-regulated protein 78 kDa, BiP) in the lumen of
the ER and the binding with endoplasmic reticulum protein
retention (KDEL) receptors located on Golgi apparatus and
cell surface (Glembotski et al., 2012; Henderson et al., 2013).
In pathological conditions with elevated ER-stress, reduced
ER calcium level interferes with the binding of MANF and
GRP78. ER-stress also induces protein transportation from the
ER to Golgi, resulting in an accumulation of MANF and
GRP78 in the lumen of Golgi. GRP78 competes with MANF
on the binding with KDEL receptors, leading to a decreased
retention of MANF in the ER. MANF has been implicated
as a neurotrophic factor that regulates neuron development
and protects neuron from various pathological conditions
(Li-Na et al., 2017; Lindahl et al., 2017). The mechanisms
involved in the neuroprotective role of MANF remains unclear,
although increasing evidence has suggested the involvement of
MANF in ameliorating ER-stress induced apoptosis (Lindahl
et al., 2017; Xu M. et al., 2018; Zhang et al., 2017a; Zhang
et al., 2017b; Zhu et al., 2016). There are inconsistent
reports regarding the role of intracellular and extracellular
MANF in the context of neuroprotection. For example,
extracellular application of MANF was reported to protect
neurons and myocardial cells from ischemic injuries (Tadimalla
et al., 2008; Airavaara et al., 2009; Glembotski et al., 2012),
while MANF had to be injected directly into neurons to
protect against Bax-dependent apoptosis or overexpressed
intracellularly in Hela cells to improve cell viability under
glucose-free conditions and tunicamycin treatment (Apostolou
et al., 2008; Hellman et al., 2011). We showed that either
overexpression of MANF intracellularly by adenovirus or
addition of recombinant hMANF into cell culture can induce
longer neurite outgrowth in response to RA stimulation.
However, the addition of MANF in the culture media did
not rescue neurite growth in MANF KO cells, indicating
that the intracellular MANF plays an important role that is
not compensated by MANF in the culture media. One of
the limitations of this study is that we were not able to
exclude the secretion of adenovirus-mediated MANF from
cells, which makes it difficult to distinguish the function of
intracellular and extracellular MANF. To further study the
function of MANF in these two forms, we need to determine
if the intracellularly overexpressed MANF can also increase
the level of MANF being secreted and if blocking MANF
secretion will affect the role of MANF in facilitating RA-induced
neurite outgrowth.
PI3K/Akt and Ras/Erk pathways are important intracellular
signal transduction cascades that are critical for fundamental
cellular functions, regulating cell proliferation, growth, survival,
mobility and cell death (McCubrey et al., 2007; Mendoza
et al., 2011). They are often dysregulated in human cancers,
leading to aberrant activation of the signaling cascades (Asati
et al., 2016). Disturbed activation of the PI3K/Akt/ and
Ras/Erk pathways are oncogenic, enhancing the growth, survival,
and metabolism of cancer cells (Jokinen and Koivunen,
2015). PI3K/Akt and Ras/Erk signaling pathways are also
key mediators for neuronal survival and several aspects
of neurite outgrowth, including cell skeleton reorganization
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at the concentrations we used, although inhibitors appeared
to slightly reduce cell density. In general, it is easier for N2a
cells to extend longer neurite at lower density, however, we
observed reduced neurite outgrowth in RA and RA+MANF
groups after inhibitor treatments. As a result, we believe that
the effect of these inhibitors on neurite outgrowth did not
result from the potential toxicity and alterations in cell density,
rather than through the activation of Akt/mTOR and Erk/mTOR
signaling cascades.
In line with the insufficient activation of Akt/mTOR and
Erk/mTOR signaling pathways, we also observed impaired
protein synthesis in MANF deficient cells. Consistent with
previous report that decreased protein synthesis was also
observed in cultured MANF −/− mice NSCs (Tseng et al.,
2017b), our results suggest that the impaired protein synthesis
may contribute to the defect of neurite outgrowth in MANF
knockout cells.
Our data indicate that MANF facilitates RA-induced neurite
outgrowth by positively regulating Akt/mTOR and Erk/mTOR
signaling pathways. However, the mechanisms by which MANF
activates the Akt/mTOR and ERK/mTOR signaling pathways
are currently unknown. In addition, in the experiment of
treating MANF KO cells with RA and Akt, Erk or mTOR
activators, except for a mild neurite outgrowth in Akt plus Erk
activators treated group, none of the other groups showed a
rescue in neurite outgrowth. This data indicates that besides
Akt/mTOR and Erk/mTOR signaling pathways, there must be
other signaling pathways or cellular processes that are affected by
MANF knockout and are also important for RA-induced neurite
outgrowth. ER stress can be one of the candidate mechanisms, as
MANF is known to alleviate ER stress and elevated ER stress is
associated with many neurodegenerative diseases and defects in
neurite outgrowth (Kawada et al., 2018).
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SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online
at:
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560020/full#supplementary-material
Supplementary Figure S1 | Expression of exogenous MANF in N2a cells after
adenovirus transduction. (A) Protein was extracted from cells transduced with
AD-vector and AD-MANF at 24, 48, 72, 96, and 120 h after transduction, then
subjected to immunoblot. The expression of HA tag and MANF was examined.
β-actin was used as a loading control. The size of the proteins (kDa) was labeled
next to each band. (B) Exogenous MANF protein levels were quantified as relative
levels normalized to β-actin. Two-way ANOVA followed with the Bonferroni’s
post hoc test, ∗∗ P < 0.01, ∗∗∗ P < 0.0001. The data were expressed as the
mean ± SEM of three independent experiments.

CONCLUSION

Supplementary Figure S2 | MANF cannot be reintroduced into MANF KO cells.
(A) Immunofluorescent images showing control and MANF KO cells were
transduced with AD-vector and AD-MANF and then immunolabeled with HA tag
(green) and MANF (red). Cell nuclei were stained by DAPI. (B) The percentage of
cells with HA tag expression was quantified. Student’s t-test, ∗∗∗ P < 0.0001. The
data were expressed as the mean ± SEM of three independent experiments. (C)
Protein was extracted from cells 36 h after being incubated with AD-vector and
AD-MANF for 1–4 h, and then subjected to immunoblot with HA tag and MANF
antibodies. β-actin was used as a loading control. (D) Protein was extracted from
control and MANF KO cells, and then immunoblot with Cas9 antibody. β-actin was
used as a loading control. The size of the proteins (kDa) was labeled next to each
band. The experiment was replicated three times.

In conclusion, our study demonstrated that MANF deficiency
attenuates RA-induced neurite outgrowth and MANF
overexpression facilitates the growth of longer neurites.
This is the first study to demonstrate that MANF regulate neurite
outgrowth through activating Akt/mTOR and Erk/mTOR
signaling pathways and protein synthesis. This study provides
evidence that MANF is involved in neuronal differentiation and
it may be a potential candidate to facilitate the regeneration of
neuronal processes in neurodegenerative diseases.

Supplementary Figure S3 | The effect of pharmacological inhibition or activation
of Akt, Erk and mTOR on the expression of p-Akt, p-Erk, and p-mTOR in
response to RA treatment. (A) Quantification of p-Akt, p-Erk, p-mTOR, and
p-P70S6 protein expression in control cells treated with DMSO, RA or
RA+inhibitors. β-actin was used as a loading control. One-way ANOVA followed
with the Tukey’s post hoc test, ∗ P < 0.05, ∗∗ P < 0.01 compared to DMSO treated
group; # P < 0.05, ## P < 0.01, ### P < 0.001 compared to RA treated group. The
data were expressed as the mean ± SEM of three independent experiments. (B)
Quantification of p-Akt, p-Erk, p-mTOR, and p-P70S6 protein expression in MANF
KO cells treated with DMSO, RA or RA+activators. β-actin was used as a loading
control. One-way ANOVA followed with the Tukey’s post hoc test, n.s. not
statistically significant, ∗ P < 0.05 compared to DMSO treated group; # P < 0.05
compared to RA treated group. The data were expressed as the mean ± SEM of
three independent experiments.
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